---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-24-000031"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T23:09:33.231448+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biohaven presents BHV-1300 Ph1 SAD data: safe, dose-dependent IgG lowering in 16 subjects

## Summary
- 16 subjects completed two dosing cohorts; no SAEs, only mild AEs unrelated to drug.
- Preliminary dose- and time-dependent IgG lowering observed; IgG1/2/4 reduction greater than IgG3.
- BHV-1300 designed to spare IgG3; data consistent with preclinical nonhuman primate models.
- Further program update planned at Company's R&D Day on May 29, 2024.

## SEC filing metadata
- accession: 0001935979-24-000031
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000031/0001935979-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000031/bhvn-20240415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-24-000031
- JSON: https://secwatch.observer/filing/0001935979-24-000031.json
- Plain text: https://secwatch.observer/filing/0001935979-24-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.